These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24304170)

  • 21. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
    Ahn CH; Kim EK; Min SH; Oh TJ; Cho YM
    Diabetes Obes Metab; 2017 Mar; 19(3):457-462. PubMed ID: 27868366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
    Kim E; Park KR; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2019; 13():3879-3885. PubMed ID: 32009778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [
    Lu J; Bian Y; Zhang H; Tang D; Tian X; Zhou X; Xu Z; Xiong Y; Gu Z; Yu Z; Wang T; Ding J; Yu Q; Ding J
    Xenobiotica; 2022 Jan; 52(1):38-45. PubMed ID: 34743655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
    Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
    Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
    Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK
    Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.
    Vermeir M; Naessens I; Remmerie B; Mannens G; Hendrickx J; Sterkens P; Talluri K; Boom S; Eerdekens M; van Osselaer N; Cleton A
    Drug Metab Dispos; 2008 Apr; 36(4):769-79. PubMed ID: 18227146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys.
    Kuhlmann O; Paehler A; Weick I; Funk C; Pantze M; Zell M; Timm U
    Xenobiotica; 2010 Dec; 40(12):840-52. PubMed ID: 20868265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Oct; 39(10):1010428317722068. PubMed ID: 28982310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
    Lim KS; Cho JY; Kim BH; Kim JR; Kim HS; Kim DK; Kim SH; Yim HJ; Lee SH; Shin SG; Jang IJ; Yu KS
    Br J Clin Pharmacol; 2009 Dec; 68(6):883-90. PubMed ID: 20002082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.
    Kochansky CJ; Rippley RK; Yan KX; Song H; Wallace MA; Dean D; Jones AN; Lasseter K; Schwartz J; Vincent SH; Franklin RB; Wagner J
    Drug Metab Dispos; 2006 Sep; 34(9):1457-61. PubMed ID: 16772365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Endocrinol Invest; 2018 Jun; 41(6):677-689. PubMed ID: 29147952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
    Choi SH; Leem J; Lee IK
    Mediators Inflamm; 2017; 2017():4139439. PubMed ID: 29317794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.